Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

S5701

Sigma-Aldrich

SR 49059

≥97% (HPLC)

Synonym(s):

(2S)-1-[[(2R,3S)-5-Chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide, SR49059

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C28H27Cl2N3O7S
CAS Number:
150375-75-0
Molecular Weight:
620.50
MDL number:
MFCD00922133
UNSPSC Code:
51111800
PubChem Substance ID:
329824460
NACRES:
NA.77

Assay

≥97% (HPLC)

form

powder

optical activity

[α]/D -180 to -190°, c = 0.3 in chloroform-d

color

white to off-white

solubility

DMSO: ≥10 mg/mL

originator

Sanofi Aventis

storage temp.

2-8°C

SMILES string

COc1ccc(cc1OC)S(=O)(=O)N2[C@@H](C(=O)N3CCC[C@H]3C(N)=O)[C@@](O)(c4ccccc4Cl)c5cc(Cl)ccc25

InChI

1S/C28H27Cl2N3O7S/c1-39-23-12-10-17(15-24(23)40-2)41(37,38)33-21-11-9-16(29)14-19(21)28(36,18-6-3-4-7-20(18)30)25(33)27(35)32-13-5-8-22(32)26(31)34/h3-4,6-7,9-12,14-15,22,25,36H,5,8,13H2,1-2H3,(H2,31,34)/t22-,25-,28+/m0/s1

InChI key

CEBYCSRFKCEUSW-NAYZPBBASA-N

Gene Information

human ... AVPR1A(552) , OXTR(5021)

Application

SR 49059 has been used to study the V1AR (vasopressin type 1A receptor) signaling mediated β adrenergic receptor responsiveness and its contribution to the development of heart failure.
SR 49059 may be used in Arginine Vasopressin (AVP) V1a-receptor-mediated cell signaling studies.

Biochem/physiol Actions

SR 49059 is a potent and selective Arginine Vasopressin (AVP) V1a-receptor antagonist. AVP is a hormone that plays an important part in circulatory and water homoeostasis and is important in renal hemodynamic alterations, water retention, and cardiac remodeling in congestive heart failure (CHF). There are three AVP receptor subtypes V1a, V1b, and V2. All belong to the large rhodopsin-like G-protein-coupled receptor family. V(1a) antagonists improve water balance and cardiac hypertrophy in CHF and might be beneficial for the treatment of water retention and cardiac remodeling in CHF. SR 49059 has also shown initial positive results in the treatment of Raynaud′s disease, dysmenorrhoea, and tocolysis.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class Code

11 - Combustible Solids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Margareta Steinwall et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 20(2), 104-109 (2005-04-13)
Relcovaptan (SR 49059) is a non-peptide, orally active vasopressin V1a receptor inhibitor. The effect on uterine contractions in 18 women with preterm labor in pregnancy weeks 32-36 was assessed in a double-blind investigation. The inclusion criterion was at least four
Owen Jeffries et al.
Investigative ophthalmology & visual science, 51(3), 1591-1598 (2009-12-05)
To investigate the effects of arginine vasopressin (AVP) on Ca(2+) sparks and oscillations and on sarcoplasmic reticulum (SR) Ca(2+) content in retinal arteriolar myocytes. Fluo-4-loaded smooth muscle in intact segments of freshly isolated porcine retinal arteriole was imaged by confocal
Véronique Perraudin et al.
The Journal of clinical endocrinology and metabolism, 91(4), 1566-1572 (2006-02-02)
Arginine vasopressin (AVP) stimulates steroid secretion from the normal human adrenal gland and some cortisol-producing adrenocortical tumors or hyperplasia through activation of the V(1a) receptor. The objective of the study was to investigate in vitro and in vivo the possible
Junko Tsukada et al.
Vascular pharmacology, 42(2), 47-55 (2005-02-22)
The pharmacologic profile of YM218, (Z)-4'-{4,4-difluoro-5-[2-oxo-2-(4-piperidinopiperidino)ethylidene]-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl}-2-methyl-3-furanilide hemifumarate, a newly synthesized, nonpeptide vasopressin (AVP) receptor antagonist, was investigated using several in vitro and in vivo methods. YM218 exhibited high affinity for V1A receptors isolated from rat liver, with a Ki value
Virginie Bernier et al.
Journal of the American Society of Nephrology : JASN, 17(1), 232-243 (2005-12-02)
In many mendelian diseases, some mutations result in the synthesis of misfolded proteins that cannot reach a transport-competent conformation. In X-linked nephrogenic diabetes insipidus, most of the mutant vasopressin 2 (V2) receptors are trapped in the endoplasmic reticulum and degraded.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service